Rhenman & Partners Asset Management AB
About Rhenman & Partners Asset Management AB’s 13F portfolio
Rhenman & Partners Asset Management AB is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Rhenman & Partners Asset Management AB reported $1.1B across 99 US-listed positions (). Its largest position is UNITED HEALTH GROUP INC (UNH) at 3.7% of the reported book, and its ten biggest holdings make up 25% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NYSE: UNH UNITED HEALTH GROUP INC | $339.85 +2.84% | 3.7% | 94K | $38.9M |
| 2 | NYSE: CVS CVS HEALTH CORP | $80.84 +1.00% | 2.7% | 279K | $28.9M |
| 3 | NASDAQ: AZN ASTRAZENECA PLC | $174.35 −0.60% | 2.7% | 152K | $28.5M |
| 4 | NYSE: MRK MERCK & CO INC | $133.72 +0.69% | 2.6% | 214K | $27.4M |
| 5 | NYSE: LLY LILLY ELI & CO | $1,347.11 −0.30% | 2.5% | 22K | $26.8M |
| 6 | NYSE: ABBV ABBVIE INC | $286.20 +0.94% | 2.3% | 97K | $24.4M |
| 7 | NASDAQ: ALHC ALIGNMENT HEALTHCARE INC | $6.37 −2.00% | 2.2% | 997K | $23.7M |
| 8 | NYSE: EW EDWARDS LIFESCIENCES CORP | $101.85 −1.95% | 2.2% | 260K | $23.5M |
| 9 | NASDAQ: GILD GILEAD SCIENCES INC | $166.43 −0.06% | 2.1% | 178K | $22.5M |
| 10 | NASDAQ: JAZZ JAZZ PHARMACEUTICALS PLC | $230.26 −2.62% | 2.0% | 87K | $21.1M |
| 11 | NASDAQ: BIIB BIOGEN INC | $249.59 +1.00% | 1.9% | 95K | $20.5M |
| 12 | NYSE: SYK STRYKER CORPORATION | $310.00 −0.98% | 1.9% | 65K | $20.5M |
| 13 | NYSE: BSX BOSTON SCIENTIFIC CORP | $41.98 −2.35% | 1.8% | 451K | $19.2M |
| 14 | NYSE: JNJ JOHNSON & JOHNSON | $270.47 +1.25% | 1.7% | 73K | $18.4M |
| 15 | NASDAQ: GH GUARDANT HEALTH INC | $145.83 +0.16% | 1.6% | 115K | $17.3M |
| 16 | NASDAQ: REGN REGENERON PHARMACEUTICALS | $920.69 −0.29% | 1.6% | 27K | $17.1M |
| 17 | NYSE: GKOS GLAUKOS CORP | $237.31 −0.33% | 1.6% | 119K | $16.6M |
| 18 | NASDAQ: BMRN BIOMARIN PHARMACEUTICAL INC | $60.41 −1.64% | 1.6% | 291K | $16.6M |
| 19 | NASDAQ: NRIX NURIX THERAPEUTICS INC | $12.85 −5.51% | 1.6% | 684K | $16.6M |
| 20 | NASDAQ: NTRA NATERA INC | $273.40 −5.70% | 1.6% | 61K | $16.6M |
| 21 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | $96.13 +0.65% | 1.5% | 139K | $16.3M |
| 22 | NASDAQ: INSM INSMED INC | $141.33 −2.17% | 1.5% | 152K | $16.2M |
| 23 | NYSE: THC TENET HEALTHCARE CORP | $263.19 −0.15% | 1.5% | 85K | $15.9M |
| 24 | NYSE: TMO THERMO FISHER SCIENTIFIC INC | $669.54 −2.79% | 1.5% | 32K | $15.8M |
| 25 | NYSE: CNC CENTENE CORP DEL | $63.78 −2.74% | 1.5% | 244K | $15.7M |
Showing 1–25 of 99 positions on this page reported in this 13F.
- Healthcare100%
- AddedUNHUNITED HEALTH GROUP INC+106%$38.9M
- NewAZNASTRAZENECA PLC—$28.5M
- NewMRKMERCK & CO INC—$27.4M
- AddedABBVABBVIE INC+35.2%$24.4M
- AddedEWEDWARDS LIFESCIENCES CORP+59.5%$23.5M
- AddedGILDGILEAD SCIENCES INC+6.3%$22.5M
- AddedJAZZJAZZ PHARMACEUTICALS PLC+15.2%$21.1M
- AddedSYKSTRYKER CORPORATION+36.0%$20.5M
- NewJNJJOHNSON & JOHNSON—$18.4M
- AddedGKOSGLAUKOS CORP+41.7%$16.6M
- ReducedCVSCVS HEALTH CORP−17.0%$28.9M
- ReducedLLYLILLY ELI & CO−33.8%$26.8M
- ReducedALHCALIGNMENT HEALTHCARE INC−5.4%$23.7M
- ReducedBIIBBIOGEN INC−13.1%$20.5M
- ReducedBSXBOSTON SCIENTIFIC CORP−27.9%$19.2M
- ReducedGHGUARDANT HEALTH INC−20.7%$17.3M
- ReducedREGNREGENERON PHARMACEUTICALS−43.1%$17.1M
- ReducedINSMINSMED INC−4.9%$16.2M
- ReducedTMOTHERMO FISHER SCIENTIFIC INC−23.6%$15.8M
- ReducedAXSMAXSOME THERAPEUTICS INC.−1.2%$15.4M
Reading Rhenman & Partners Asset Management AB’s 13F portfolio
Rhenman & Partners Asset Management AB’s $1.1B 13F book is spread across 99 reported positions and is moderately diversified, the ten largest names accounting for 25%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are UNH, CVS, AZN, MRK and LLY, led by UNITED HEALTH GROUP INC (UNH) at 3.7% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Rhenman & Partners Asset Management AB changed last quarter
Between 2026-03-31 and Q2 2026, Rhenman & Partners Asset Management AB was a net buyer: it opened 21 new positions and added to 41 more, while trimming 34 and closing 8 outright. Against a 99-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was UNITED HEALTH GROUP INC (UNH), and its biggest reduction was CVS HEALTH CORP (CVS).
What a 13F does and doesn’t reveal
A 13F captures only Rhenman & Partners Asset Management AB’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Rhenman & Partners Asset Management AB is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Rhenman & Partners Asset Management AB's profile on this page is built directly from those filings.
How current is the 13F data on Rhenman & Partners Asset Management AB's page?
It reflects Rhenman & Partners Asset Management AB's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Rhenman & Partners Asset Management AB files its next quarterly report, this page refreshes automatically.
Can I see Rhenman & Partners Asset Management AB's complete list of holdings?
This page highlights Rhenman & Partners Asset Management AB's largest positions rather than all 99 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Rhenman & Partners Asset Management AB's filings.
Does a 13F show everything Rhenman & Partners Asset Management AB owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Rhenman & Partners Asset Management AB's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Rhenman & Partners Asset Management AB made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

